New Product Newswire for November 17, 2003
FDA Approves Losartan Potassium for Reduction in Risk of Stroke
The new approval is an oral suspension for patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy.
Episode 8: Stay in Sync with Innovations in Medication Decision Support
Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.
FDA Grants Orphan Drug Designation to BIOX-101 for Intracerebral Hemorrhagic Stroke
Currently, there is a gap in treatment for this patient population and intracerebral hemorrhagic stroke is considered an orphan disease.
FDA Approves neffy for Treatmet of Type 1 Allergic Reactions, Anaphylaxis
The approval is the first significant innovation for the delivery of epinephrine for this population in more than 35 years, according to the company news release.
FDA Approves Denosumab-Bmwo as Biosimilar to Prolia, Xgeva
Denosumab-Bmwo is approved for all indications of the respective reference products, including osteoporosis and high-risk of fracture due to chemotherapy.
Depemokimab Demonstrates Significant Improvements in Rhinosinusitis with Nasal Polyps
GSK announced its ANCHOR-1 and ANCHOR-2 phase 3 trial results for depemokimab’s efficacy and safety in treating patients with chronic rhinosinusitis with nasal polyps.
